Buy Dostinex (Cabergoline) tablets 0.5mg No. 2 and No. 8 online. Free worldwide shipping.
Brand: Pfizer
Drug form: tablets
Manufacturers: Italia S.r.l. (Italy), Pharmacy and Upjohn (Italy)
Active substance: cabergoline
Group: Dopamine and dopaminergic drugs
Expiration date: 2 years
More about the drug in Russian
We accept all the major cards including Visa, Maestro, Master Card and other. All the transactions are 100% secure and backed by Stripe financial services. Read more about the service.
We undertake all fees for the delivery and currency exchange.
Feel free to contact us in case of any questions: manager@befitpharma.com
DOSTINEX (Cabergoline) tablets 0.5mg No. 2 and No. 8
Indications for use of Dostinex are:
Prevention of physiological lactation after childbirth. Suppression of already established postpartum lactation. Treatment of disorders associated with hyperprolactinemia, including amenorrhea, oligomenorrhea, anovulation, galactorrhea. Prolactin-secreting pituitary adenomas (micro- and macroprolactinomas); idiopathic hyperprolactinemia; syndrome of "empty" Turkish saddle in combination with hyperprolactinemia.
pharmachologic effect
Pharmacodynamics. Cabergoline is a dopaminergic derivative of ergoline and is characterized by a pronounced and long-term prolactin-lowering effect due to direct stimulation of D2-dopamine receptors of pituitary lactotropic cells. In addition, when higher doses are taken, but compared with those to reduce the concentration of prolactin in blood plasma, cabergoline has a central dopaminergic effect due to stimulation of D2 receptors. A decrease in the concentration of prolactin in blood plasma is noted within 3 hours after taking the drug and persists for 7-28 days in healthy volunteers and patients with hyperprolactinemia, and up to 14-21 days in women in the postpartum period. Cabergoline has a strictly selective effect, does not affect the basal secretion of other pituitary hormones and cortisol. The prolactin-lowering effect of cabergoline is dose-dependent in terms of both severity and duration of action. The pharmacodynamic effects of cabergoline, which are not associated with a therapeutic effect, include only a decrease in blood pressure (BP). With a single dose of the drug, the maximum hypotensive effect is observed within the first 6 hours and is dose-dependent. Pharmacokinetics. Cabergoline is rapidly absorbed from the gastrointestinal tract, the maximum concentration in blood plasma is reached after 0.5-4 hours, the connection with blood plasma proteins is 41-42%. The half-life of cabergoline, assessed by the rate of excretion by the kidneys, is 63-68 hours in healthy volunteers and 79-115 hours in patients with hyperprolactinemia. Due to the long half-life, the state of equilibrium concentration is reached after 4 weeks. 10 days after taking cabergoline in urine and feces, about 18% and 72% of the dose taken, respectively, are found, and the proportion of unchanged cabergoline in urine is 2-3%. The main metabolic product of cabergoline identified in urine is 6-allyl-8beta-carboxy-ergoline at a concentration of up to 4-6% of the dose taken. The content of 3 additional metabolites in urine does not exceed 3% of the dose taken. It was found that metabolic products have a significantly lower effect in suppressing the secretion of prolactin in comparison with cabergoline. Food intake does not affect the absorption and distribution of cabergoline.